Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats

被引:22
作者
Sezgin Bayindir, Zerrin [1 ]
Besikci, Arzu [2 ]
Yuksel, Nilufer [1 ]
机构
[1] Ankara Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
[2] Ankara Univ, Fac Pharm, Dept Pharmacol, TR-06100 Ankara, Turkey
关键词
Niosomes; Span; 40; paclitaxel; pharmacokinetics; tissue distribution; TARGETED DRUG-DELIVERY; ACTIVATED MACROPHAGES; BOLA-SURFACTANT; EFFICACY; PEG; ENHANCEMENT; COMBINATION; CISPLATIN; MICELLES; SYSTEMS;
D O I
10.3906/sag-1408-129
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: The purpose of this study was to investigate and compare the pharmacokinetic behavior and tissue distribution of paclitaxel, delivered as commercial preparation Taxol or through Span 40 niosomes, after intravenous injection to rats. Materials and methods: Paclitaxel-loaded Span 40 niosomes were prepared using the thin-film method. An HPLC method was developed and validated for paclitaxel determination in rat plasma and tissues. Results: The area under the curve value of the niosome-recipient group (3.22 +/- 0.255 mu g h/mL) was significantly higher compared to that of the Taxol group (0.725 +/- 0.163 mu g h/mL). The mean residence time and the elimination half-life of paclitaxel were 1.66 +/- 0.133 h and 1.15 +/- 0.085 h for Taxol administration, respectively. The elimination half-life (7.63 +/- 0.380 h) and the mean residence time (11.0 +/- 0.6 h) of paclitaxel were significantly increased, and a pronounced delay was observed in general excretion of paclitaxel from plasma (0.0925 +/- 0.00490 h(-1)) after niosomal administration. The spleen was the main tissue that accumulated paclitaxel from both niosomes and Taxol. Conclusion: The findings of this study show that niosomal formulation might be a useful drug delivery system for intravenous administration of paclitaxel.
引用
收藏
页码:1403 / 1412
页数:10
相关论文
共 44 条
[1]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[2]  
[Anonymous], GUID IND BIOAN METH
[3]   Niosomes in sustained and targeted drug delivery: some recent advances [J].
Azeem, Adnan ;
Anwer, Md. Khalid ;
Talegaonkar, Sushama .
JOURNAL OF DRUG TARGETING, 2009, 17 (09) :671-689
[4]   Targeted drug delivery to tumors: Myths, reality and possibility [J].
Bae, You Han ;
Park, Kinam .
JOURNAL OF CONTROLLED RELEASE, 2011, 153 (03) :198-205
[5]   Characterization of Niosomes Prepared With Various Nonionic Surfactants for Paclitaxel Oral Delivery [J].
Bayindir, Zerrin Sezgin ;
Yuksel, Nilufer .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (04) :2049-2060
[6]   Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil [J].
Cosco, D. ;
Paolino, D. ;
Muzzalupo, R. ;
Celia, C. ;
Citraro, R. ;
Caponio, D. ;
Picci, N. ;
Fresta, M. .
BIOMEDICAL MICRODEVICES, 2009, 11 (05) :1115-1125
[7]  
European Medicines Agency, 2008, ASS REP ABR
[8]  
Food and Drug Administration, 2014, ICH HARM TRIP GUID V
[9]   Antimetastatic efficacy of niosomal pentoxifylline and its combination with activated macrophages in murine B16F10 melanoma model [J].
Gaikwad, SY ;
Jagtap, AG ;
Ingle, AD ;
Ra, SGA ;
Gude, RP .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (06) :605-615
[10]   Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation [J].
Gelderblom, H ;
Verweij, J ;
Nooter, K ;
Sparreboom, A .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) :1590-1598